Male/female | 25/33 |
Age, yrs, median (25th–75th percentile) | 51.5 (45.5–59) |
Disease duration, yrs, median (25th–75th percentile) | 8.05 (6–15) |
Articular manifestations, % | |
Peripheral arthritis | 74.1 |
Enthesitis | 20.6 |
Dactylitis | 29.3 |
Extraarticular manifestations, % | |
Uveitis | 8.6 |
IBD | 1.7 |
HLA-B27 | 22.4 |
Indices and other measures, median (25th–75th percentile) | |
DAPSA | 24.7 (16.6–38.7) |
Tender joint | 2 (0–6) |
Swollen joint | 0 (0–2) |
ESR, mm/h | 19.5 (8.7–27.25) |
CRP, mg/dl | 0.55 (0.21–1.25) |
VAS global | 60 (45–70) |
VAS pain | 60 (45–76.25) |
VAS back pain | 47.5 (25–73.5) |
VAS physician | 45 (39.25–58.75) |
BASDAI | 5.95 (5–7.2) |
HAQ | 1 (0.62–1.5) |
PASI | 0 (0–1.9) |
MASES | 1 (0–3) |
Concomitant treatment at baseline, n (%) | |
DMARD | 20 (34.4) |
Prednisone intake | 16 (27.5) |
NSAID intake | 40 (68.9) |
Anti-TNF therapy, n (%) | |
Adalimumab | 15 (25.8) |
Etanercept | 30 (51.7) |
Golimumab | 13 (22.5) |
PsA: psoriatic arthritis; IBD: inflammatory bowel disease; DAPSA: Disease Activity Index for Psoriatic Arthritis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein, VAS: visual analog scale; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; HAQ: Health Assessment Questionnaire; PASI: Psoriasis Area Severity Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score, DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal antiinflammatory drugs; TNF: tumor necrosis factor.